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Letters to the EditorFibroStic: A large conﬁrmatory study for non-invasive
biomarkers accuracy, if correctly interpretedTo the Editor:
The article by Degos et al. assessing the diagnostic accuracy of
Fibroscan compared to liver ﬁbrosis biomarkers in chronic viral
hepatitis is an interesting multicenter study, but several major
ﬂaws rendered the conclusions hazardous [1].
First, the design induced a high risk of selection bias. During
the study inclusion period, biomarkers were already being widely
used in France with an obvious selection of patients, i.e. all the
patients included from our center had biopsy because of a signif-
icant discordance between FibroTest and elastography [2]. This
was too late to be representative of näive patients without a
selection bias. The authors compared patients with and without
prior non-invasive marker use, but this was not the point. They
should have identiﬁed patients who had discordance between
tests or inapplicable tests leading to the indication of biopsy, in
the different tertiary centers, in order to prevent the selection
bias.
Second, the conclusion that ‘‘the diagnostic accuracy of non-
invasive tests was high for cirrhosis but poor for signiﬁcant ﬁbro-
sis’’ is a caricature of a spectrum effect. An accuracy deﬁned by
AUROC of 0.90 for cirrhosis is mathematically equivalent to an
AUROC of 0.78 for signiﬁcant ﬁbrosis [3,4]. The authors should
have used the Obuchowski method to assess all pairwise compar-
isons between ﬁbrosis stages to prevent this spectrum effect, as
was already recommended [4].
Third, the authors underestimated the risk of false positives/
negatives of a 20 mm biopsy in chronic hepatitis C. They stated
that the performance of biopsy can be improved ‘‘by using an
appropriate specimen length and number of portal tracts, as we
have done in this study’’. They forgot to mention that the risk
of error of a 20 mm liver biopsy is 30% for false negatives/posi-
tives using large surgical samples [5]. Therefore, they should have
used at least one of the appropriate statistical methods they cited
and not only those such as multilevel likelihood ratios, which
need a perfect reference [6]. Test validation is probably the way
to go in case there is a test that is proclaimed to be ‘better than
(or at least similar to) the existing reference standard’ [7]. In
these cases also, we have to show that the differences between
that test and the reference standard are ‘meaningful’ by demon-
strating reliable associations with other ﬁndings. Clinical end-
points belong to this ‘‘test validation’’ and the authors should
have commented on previously published studies that observed
a similar or better prognostic value of biomarkers versus biopsy
for the prediction of treatment response [8], and for the prediction
of morbidity or mortality in patients with chronic hepatitis C [9].
Finally, the only scientiﬁc result from this study is conﬁrma-
tory: the accuracy of biomarkers and elastography is similar both
for cirrhosis and signiﬁcant ﬁbrosis when using biopsy as a per-
fect reference. Furthermore these results, when correctly dis-
cussed, fully support the ﬁrst recommendations from the
French National Authority for Health for FibroTest and elastogra-
phy as ﬁrst-line estimates of ﬁbrosis in patients with chronic
hepatitis C in December 2006 and their use by French hepatolo-
gists [2].
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